The importance of the methodology and sample matrix when interpreting chromogranin A results

Peter A Kavsak^{1

2

3}, John Beattie³, Angela C Rutledge⁴

Affiliations

¹ Juravinski Hospital and Cancer Centre, 711 Concession Street, Hamilton, L8V 1C3 ON Canada.
² McMaster University, Hamilton, ON, Canada.
³ Hamilton Health Sciences, Hamilton, ON, Canada.
⁴ London Health Sciences Centre and Western University, London, ON, Canada.

Peter A Kavsak et al. Clin Chem Lab Med. 2019.

. 2019 Oct 25;57(11):e291-e293.

doi: 10.1515/cclm-2019-0358.

Peter A Kavsak^{1

2

3}, John Beattie³, Angela C Rutledge⁴

¹ Juravinski Hospital and Cancer Centre, 711 Concession Street, Hamilton, L8V 1C3 ON Canada.
² McMaster University, Hamilton, ON, Canada.
³ Hamilton Health Sciences, Hamilton, ON, Canada.
⁴ London Health Sciences Centre and Western University, London, ON, Canada.

No abstract available

Keywords: Kryptor; chromogranin A; immunoassay; matrix.

References

1. Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, et al. ENETS consensus guidelines for standard of care in neuroendocrine tumours: biochemical markers. Neuroendocrinology 2017;105:201–11.
1. Mosli HH, Dennis A, Kocha W, Asher LJ, Van Uum SH. Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects. J Clin Endocrinol Metab 2012;97:E1731–5.
1. Krabbe JG, Monaghan PJ, Russell J, de Rijke YB. Analytical evaluation of a second generation assay for chromogranin A; a dual-site study. Clin Chem Lab Med 2016;54:e139–42.
1. Popovici T, Moreira B, Schlageter MH, Bories PN. Automated two-site immunofluorescent assay for the measurement of serum chromogranin A. Clin Biochem 2014;47:87–91.
1. Kavsak PA, Roy C, Malinowski P, Clark L, Lamers S, Bamford K, et al. Sample matrix and high-sensitivity cardiac troponin I assays. Clin Chem Lab Med. 2019;57:745–51.